Abstract
This case describes a young patient presenting with severe chronic hand eczema despite topical corticosteroid treatment with a preference for nonsystemic treatment. She has a Dermatology Life Quality Index (DLQI) score of 12. She has marked clinical improvement after 8 months of topical delgocitinib treatment, demonstrating the emerging role of topical pan-Janus kinase inhibitors as second-line therapy.